Ascendis Capital Lease Obligations from 2010 to 2025
| ASND Stock | USD 157.94 0.34 0.21% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 113.6 M | Current Value 119.3 M | Quarterly Volatility 52.4 M |
Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.6 M, Interest Expense of 68.8 M or Selling General Administrative of 298.8 M, as well as many indicators such as Price To Sales Ratio of 19.92, Dividend Yield of 0.0 or Days Sales Outstanding of 187. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
Ascendis | Capital Lease Obligations |
Latest Ascendis Pharma's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Ascendis Pharma AS over the last few years. Ascendis Pharma AS capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Ascendis Pharma asset purchases. For example, Ascendis Pharma can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Ascendis Pharma control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Ascendis Pharma's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascendis Pharma's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Ascendis Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 42,152,719 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 124.34 | |
| Mean Deviation | 48,113,523 | |
| Median | 0.00 | |
| Standard Deviation | 52,414,155 | |
| Sample Variance | 2747.2T | |
| Range | 119.3M | |
| R-Value | 0.89 | |
| Mean Square Error | 627.7T | |
| R-Squared | 0.79 | |
| Slope | 9,765,066 | |
| Total Sum of Squares | 41208.7T |
Ascendis Capital Lease Obligations History
About Ascendis Pharma Financial Statements
Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 113.6 M | 119.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Ascendis Pharma Correlation against competitors. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.263 | Return On Assets | Return On Equity |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.